These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 21112461

  • 1. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report.
    Chen PY, Lin PY, Tien SC, Chang YY, Lee Y.
    Gen Hosp Psychiatry; 2010; 32(6):646.e9-646.e11. PubMed ID: 21112461
    [Abstract] [Full Text] [Related]

  • 2. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 3. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG, Kajdasz DK, Desaiah D, Haddad PM.
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [Abstract] [Full Text] [Related]

  • 4. [Torticollis spasmodicus as a manifestation of tardive dystonia].
    Silberbauer C, Rittmannsberger H.
    Fortschr Neurol Psychiatr; 1995 Oct; 63(10):388-92. PubMed ID: 8529987
    [Abstract] [Full Text] [Related]

  • 5. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Oct; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 6. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A.
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [Abstract] [Full Text] [Related]

  • 7. [Severe "late" dystonia after neuroleptic anxiolysis with fluspirilene].
    Kappler J, Menges C, Ferbert A, Ebel H.
    Nervenarzt; 1994 Jan; 65(1):66-8. PubMed ID: 8145878
    [Abstract] [Full Text] [Related]

  • 8. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
    Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M.
    Depress Anxiety; 2006 Jan; 23(3):178-81. PubMed ID: 16528701
    [Abstract] [Full Text] [Related]

  • 9. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG.
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 11. Tardive tremor.
    Stacy M, Jankovic J.
    Mov Disord; 1992 Jan; 7(1):53-7. PubMed ID: 1348352
    [Abstract] [Full Text] [Related]

  • 12. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J.
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [Abstract] [Full Text] [Related]

  • 13. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.
    Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF.
    Mov Disord; 1994 Jul; 9(4):441-6. PubMed ID: 7969212
    [Abstract] [Full Text] [Related]

  • 14. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
    Dunner DL, Wilson M, Fava M, Kornstein S, Munoz R, O'Reardon J, Trivedi M, Wohlreich M.
    Depress Anxiety; 2008 Jul; 25(5):E1-8. PubMed ID: 17621644
    [Abstract] [Full Text] [Related]

  • 15. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study.
    Ryu S, Yoo JH, Kim JH, Choi JS, Baek JH, Ha K, Kwon JS, Hong KS.
    J Clin Psychopharmacol; 2015 Feb; 35(1):13-21. PubMed ID: 25485636
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C.
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [Abstract] [Full Text] [Related]

  • 17. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.
    Tomita T, Yasui-Furukori N, Kaneko S.
    Clin Neuropharmacol; 2013 Feb; 36(5):175-6. PubMed ID: 24045610
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tardive gait.
    Kuo SH, Jankovic J.
    Clin Neurol Neurosurg; 2008 Feb; 110(2):198-201. PubMed ID: 17997030
    [Abstract] [Full Text] [Related]

  • 20. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.